Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in hypertensive patients with chronic kidney disease

Phase 4

Completed

• Conditions: Hypertensie; chronic kidney disease; Chronic renal diseases; 10029149

• Registration Number: NL-OMON31722
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Patients with stable chronic kidney disease and hypertension: i.e. using antihypertensive drugs and/or blood pressure >145/90mmHg when off medication.;- patients on ACE inhibitor or ARB

Exclusion Criteria

Patients with diabetes mellitus
Patients on renal replacement therapy
Pregnant patients
Using of antihypertensive which cannot be stopped
Patients on immunossuppressive therapy and active nephrotic syndrome

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint<br /><br><br /><br>- the effect of Aliskiren 300mg on MSNA<br /><br><br /><br>Primay outcome:<br /><br><br /><br>- a substantial decrease in MSNA after 6 weeks treatment with Aliskiren</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters<br /><br><br /><br>- Assessment whether normalization of MSNA is obtained after treatment with<br /><br>Aliskiren 300mg/day<br /><br><br /><br><br /><br>- Comparison of the effect on MSNA after treatment with aliskiren with the<br /><br>effects on ACEi and ARB as comared to the previous studies<br /><br><br /><br>- Effect of aliskiren on blood pressure, heart rate, PRA and kidney function.<br /><br><br /><br><br /><br>Secondary outcome:<br /><br><br /><br>- Normalization of MSNA will be obtained after treatment with Aliskiren 300mg<br /><br><br /><br><br /><br>- Treatment with Aliskiren 300mg will result in more inhibition of MSNA than<br /><br>treatment with ACEi and ARB<br /><br><br /><br>-We expect a substantial blood pressure decrease, no or little effect on heart<br /><br>rate, inhibition of PRA and no effect on kidney function. </p><br>